Literature DB >> 35821274

Effect of underdilated transjugular intrahepatic portosystemic shunt on prognosis in patients with prior splenectomy: a propensity score-matched case-control study.

Wei Yao1,2, Jia-Cheng Liu1,2, Yong-Juan Wu3, Chong-Tu Yang1,2, Shu-Guang Ju1,2, Ying-Liang Wang1,2, Chao-Yang Wang1,2, Song-Jiang Huang1,2, Yao-Wei Bai1,2, Yang Chen1,2, Tong-Qiang Li1,2, Chen Zhou1,2, Bin Xiong4,5.   

Abstract

PURPOSE: This study aimed to investigate whether underdilated transjugular intrahepatic portosystemic shunt (TIPS) could reduce the risk of hepatic encephalopathy (HE) and ameliorate impaired hepatic function in patients with a history of splenectomy.
METHODS: A retrospective case-control study was conducted with 96 patients who had prior splenectomy and TIPS placement from August 2016 to May 2022. All patients were divided into two groups based on the diameter of expansion balloon catheters, the underdilated group (6-mm balloon catheter, n = 60) and a control group (8-mm balloon catheter, n = 36). Following the 1:1 propensity score matching (PSM), 33 patients in the underdilated group and 33 patients in the control group were included.
RESULTS: During a median follow-up of 36 months, a quicker recovery in liver function after TIPS placement was showed in the underdilated group. The mean TBIL content (16.562 ± 6.549 μmol/L vs 23.871 ± 11.609 μmol/L, P = 0.019) and the mean CLIF-C AD score (41.108 ± 5.223 vs 45.100 ± 4.429, P = 0.033) in the underdilated group were significantly lower than those in the control group during 6 to 12 months after the procedure. In line with the control group, the ability to reduce portal pressure gradient (PPG) and achieve a significantly clinical remission of PVT and ascites severity was showed in the underdilated group 3 months after TIPS creation (P < 0.001). The Kaplan-Meier analysis demonstrated that no statistically significant differences were found in the cumulative incidence of no overt HE (OHE) (log-rank P = 0.383), cumulative incidence without shunt dysfunction (log-rank P = 0.283), cumulative incidence of no variceal rebleeding (log-rank P = 0.696), and survival (log-rank P = 0.341) (log-rank P = 0.341) between the two groups during the follow-up period.
CONCLUSION: For patients with prior splenectomy, it is safe to employ underdilated TIPS, as the stents will eventually self-expand to 8 mm. The present study has shown some degree of liver function preservation in the underdilated group, which may be related to slower progressive changes in the portal hemodynamics.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Prognosis; Splenectomy; Transjugular intrahepatic portosystemic shunt; Treatment

Mesh:

Year:  2022        PMID: 35821274     DOI: 10.1007/s00261-022-03600-7

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  30 in total

1.  Results of surgical treatment of uncontrollable upper gastrointestinal hemorrhage using endoscopy.

Authors:  Tsy Yeng Choy; Christian Simoens; Viviane Thill; Freddy Mboti; Shiran Vandaele; Pierre Mendes da Costa
Journal:  Hepatogastroenterology       Date:  2011 Jan-Feb

2.  Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases.

Authors:  Guadalupe Garcia-Tsao; Juan G Abraldes; Annalisa Berzigotti; Jaime Bosch
Journal:  Hepatology       Date:  2016-12-01       Impact factor: 17.425

3.  Thromboembolic Events Following Splenectomy: Risk Factors, Prevention, Management and Outcomes.

Authors:  Amihai Rottenstreich; Geffen Kleinstern; Galia Spectre; Nael Da'as; Esther Ziv; Yosef Kalish
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

4.  Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings.

Authors:  M Casado; J Bosch; J C García-Pagán; C Bru; R Bañares; J C Bandi; A Escorsell; J M Rodríguez-Láiz; R Gilabert; F Feu; C Schorlemer; A Echenagusia; J Rodés
Journal:  Gastroenterology       Date:  1998-06       Impact factor: 22.682

Review 5.  Predictors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in cirrhotic patients: a systematic review.

Authors:  Ming Bai; Xingshun Qi; Zhiping Yang; Zhanxin Yin; Yongzhan Nie; Shanshan Yuan; Kaichun Wu; Guohong Han; Daiming Fan
Journal:  J Gastroenterol Hepatol       Date:  2011-06       Impact factor: 4.029

6.  How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts.

Authors:  M Rössle; V Siegerstetter; M Olschewski; A Ochs; E Berger; K Haag
Journal:  Am J Gastroenterol       Date:  2001-12       Impact factor: 10.864

7.  Combined Rex-bypass shunt with pericardial devascularization alleviated prehepatic portal hypertension caused by cavernomatous transformation of portal vein.

Authors:  Ruo-Yi Wang; Jun-Feng Wang; Qian Liu; Nan Ma; Wei-Xiu Chen; Jin-Liang Li
Journal:  Postgrad Med       Date:  2017-06-23       Impact factor: 3.840

Review 8.  Baveno VII - Renewing consensus in portal hypertension.

Authors:  Roberto de Franchis; Jaime Bosch; Guadalupe Garcia-Tsao; Thomas Reiberger; Cristina Ripoll
Journal:  J Hepatol       Date:  2021-12-30       Impact factor: 30.083

Review 9.  TIPS: 25 years later.

Authors:  Martin Rössle
Journal:  J Hepatol       Date:  2013-06-25       Impact factor: 25.083

10.  Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors.

Authors:  O Riggio; M Merlli; G Pedretti; R Servi; P Meddi; R Lionetti; P Rossi; M Bezzi; F Salvatori; U Ugolotti; F Fiaccadori; L Capocaccia
Journal:  Dig Dis Sci       Date:  1996-03       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.